Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Rongshu Granules (FFRZKL) is a Traditional Chinese Medicine (TCM) formulation developed by Yangtze River Pharmaceutical Group for the treatment of functional constipation. It is specifically indicated for elderly patients presenting with the TCM pattern of spleen-kidney yang deficiency, which is associated with impaired intestinal motility and transit. As a compound TCM product, it consists of multiple botanical extracts that work synergistically to warm the yang and promote bowel movements. The drug is currently in Phase 3 clinical development in China, where it is being evaluated for its efficacy in increasing the frequency of complete spontaneous bowel movements (CSBM) and its safety profile over an 8-week treatment period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound rongshu granules.